Evolving Treatment Roadmap for Advanced and High-risk NMSC

Saturday, 10 Septeml 18:30–20:00 (CEST)	Der 2022 7.3.0 - Orléans Auditorium, Hall 7, Level 7.3, Paris Expo Porte de Versailles, Paris, France
18:30–18:35	Welcome and Introductions Prof Paolo Ascierto (Chair)
18:35–18:55	Current landscape in the immuno-oncology treatment of patients with NMSC Prof Paolo Ascierto
18:55–19:10	How to treat difficult cases with advanced CSCC Prof Danny Rischin
19:10-19:25	How to treat difficult cases with advanced BCC Prof Jean-Jacques Grob
19:25-19:45	What are the remaining unmet needs in clinical management of NMSC? Prof Dirk Schadendorf
19:45-20:00	Interactive Panel Discussion All Faculty



Professor Paolo Ascierto (Chair) National Tumour Institute "Fondazione G. Pascale", Naples, Italy



Professor Danny Rischin Peter MacCallum Cancer Centre, Melbourne, Australia



Professor Jean-Jacques Grob Aix-Marseille University and APHM Hospital CHU Timone, Marseille, France

sanofi



Professor Dirk Schadendorf University Hospital Essen, Essen, Germany

REGENERON

This is not a CME program. This nonpromotional event sponsored by Sanofi and Regeneron will include discussion of investigational products and products that may not be approved by the regulatory agency in your own country.

MAT-GLB-2202650 v1.0 Approval Date: 06/2022